Sage Represents BioHit Healthcare: Opportunity for Leadership in Nicotine-Free Smoking Cessation Usi

BioHit Healthcare has developed and gained approval in Europe for the Acetium® lozenge. This binds cigarette smoke-derived acetaldehyde in the saliva, thus reducing the known effects of acetaldehyde in maintaining smoking dependence. Regular use of the Acetium® lozenge during smoking increased the likelihood of smoking cessation 1.5-fold compared with placebo.

Acetium® lozenge is CE mark approved and may be sold in some countries as a food supplement.

Acetium® lozenge works by slowly releasing L-cysteine (a natural amino acid) into saliva. L-cysteine binds up to 90 % of cigarette smoke-derived acetaldehyde. The lozenge also contains xylitol, which improves oral health. Poor oral hygiene increases local acetaldehyde formation. The recommended dosage is 1 or 2 lozenges during smoking.

Acetium® lozenge:

• Removes acetaldehyde from saliva during smoking.

• Contains xylitol, which improves oral health.

• Acetium lozenge contains L-cysteine, which is a natural aminoacid. L-cysteine effectively binds acetaldehyde from saliva and forms a harmless compound that can be excreted from the body.

• L-cysteine removes over 90 per cent of the acetaldehyde dissolved into saliva during smoking.

• The recommended dosage is 1 or 2 lozenges during smoking.

• Efficacy comparable to nicotine replacement therapy and prescription drugs!

Acetium Lozenge has long lived IP

BioHit Healthcare is working with Sage Group to identify a global partner for the Acetium® lozenge for smoking cessation. The product has existing revenues which are growing rapidly.